Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder Who Have Not Adequately Responded To Treatment With A Selective Serotonin Reuptake Inhibitor.

Next Previous
Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder Who Have Not Adequately Responded To Treatment With A Selective Serotonin Reuptake Inhibitor.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ondansetron (Primary)
  • Indications Obsessive-compulsive disorders
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 17 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 21 Dec 2012 Results have been reported in a Transcept Pharmaceuticals media release.
  • 21 Dec 2012 The remaining protocol-specified analyses will be completed in early 2013 according to a Transcept Pharmaceuticals media release. The company will make a determination on any future development of ondansetron after further review of the data.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top